WHAT A DIFFERENCE A SPRAY CAN MAKE
Product shown is not actual size
CARDAMYST™ (etripamil) nasal spray is the first and only FDA-approved, self-administered treatment for adults with acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT)1,2
17 minutes median time-to-conversion with CARDAMYST vs 54 minutes with placebo1*
Patients were >2x as likely to convert to sinus rhythm within 30 minutes with CARDAMYST vs placebo1
Nasal spray delivery empowers patients to be ready anytime, anywhere a PSVT episode occurs1,2†‡
*Conversion to sinus rhythm occurred within 30 minutes during confirmed PSVT episodes in 64% of patients with CARDAMYST vs 31% with placebo. Median time to conversion was 17.2 minutes with CARDAMYST vs 53.5 minutes with placebo.1
†Patients should administer CARDAMYST in a sitting position and should not exceed 140 mg in 24 hours.1
‡Store CARDAMYST at 68 °F to 77 °F (20 °C to 25 °C), with excursions permitted from 59 °F to 86 °F (15 °C to 30 °C).1
A closer look at CARDAMYST
The first and only nasal spray for PSVT episodes.1,2
How to use CARDAMYST
Get helpful step-by-step instructions to share with your patients.
Connect with a rep
Get helpful information on CARDAMYST.